1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Nasopharyngeal Cancer Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Nasopharyngeal Cancer Treatment Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Disease Epidemiology
5.2. Pipeline Analysis
5.3. List of Drugs Approved for Nasopharyngeal Cancer
5.4. Key Industry Events (product launches/mergers, acquisitions & partnerships)
5.5. COVID-19 Pandemic Impact on Industry
6. Global Nasopharyngeal Cancer Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value & Volume Forecast, by Treatment Type, 2023–2031
6.3.1. Radiation therapy
6.3.2. Chemotherapy
6.3.3. Immunotherapy
6.3.4. Others
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Nasopharyngeal Cancer Treatment Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2023–2031
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global Nasopharyngeal Cancer Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Nasopharyngeal Cancer Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value & Volume Forecast, by Treatment Type, 2023–2031
9.2.1. Radiation therapy
9.2.2. Chemotherapy
9.2.3. Immunotherapy
9.2.4. Others
9.3. Market Value Forecast, by End-user, 2023–2031
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Others
9.4. Market Value Forecast, by Country, 2023–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment Type
9.5.2. By End-user
9.5.3. By Country
10. Europe Nasopharyngeal Cancer Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value & Volume Forecast, by Treatment Type, 2023–2031
10.2.1. Radiation therapy
10.2.2. Chemotherapy
10.2.3. Immunotherapy
10.2.4. Others
10.3. Market Value Forecast, by End-user, 2023–2031
10.3.1. Hospitals
10.3.2. Specialty Clinics
10.3.3. Others
10.4. Market Value Forecast, by Country/Sub-region, 2023–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment Type
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Nasopharyngeal Cancer Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value & Volume Forecast, by Treatment Type, 2023–2031
11.2.1. Radiation therapy
11.2.2. Chemotherapy
11.2.3. Immunotherapy
11.2.4. Others
11.3. Market Value Forecast, by End-user, 2023–2031
11.3.1. Hospitals
11.3.2. Specialty Clinics
11.3.3. Others
11.4. Market Value Forecast, by Country/Sub-region, 2023–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment Type
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Nasopharyngeal Cancer Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value & Volume Forecast, by Treatment Type, 2023–2031
12.2.1. Radiation therapy
12.2.2. Chemotherapy
12.2.3. Immunotherapy
12.2.4. Others
12.3. Market Value Forecast, by End-user, 2023–2031
12.3.1. Hospitals
12.3.2. Specialty Clinics
12.3.3. Others
12.4. Market Value Forecast, by Country/Sub-region, 2023–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Treatment Type
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Nasopharyngeal Cancer Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value & Volume Forecast, by Treatment Type, 2023–2031
13.2.1. Radiation therapy
13.2.2. Chemotherapy
13.2.3. Immunotherapy
13.2.4. Others
13.3. Market Value Forecast, by End-user, 2023–2031
13.3.1. Hospitals
13.3.2. Specialty Clinics
13.3.3. Others
13.4. Market Value Forecast, by Country/Sub-region, 2023–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of MEA
13.5. Market Attractiveness Analysis
13.5.1. By Treatment Type
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Biocon Limited
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. BeiGene Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Shanghai Junshi Biosciences Co., Ltd.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Innogene Kalbiotech
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Center of Molecular Immunology
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Bristol-Myers Squibb Company
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Merck & Co., Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Biosyngen Pte. Ltd.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
